Immix Biopharma, Inc. (IMMX) stock
IMMXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$7.20−0.28 (-3.74%)
Close on Nov 17, 2026Market cap $515.08MP/E –Yield –
Immix Biopharma operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Immix Biopharma's operating cash flow for the twelve months ending Jun 30, 2026 was -$38.50M. For fiscal 2025 it was -$23.93M. The highest annual figure on record is -$404.69K in fiscal 2020.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$23.93M | – |
| FY2024 | Dec 31, 2024 | -$14.60M | – |
| FY2023 | Dec 31, 2023 | -$11.37M | – |
| FY2022 | Dec 31, 2022 | -$7.41M | – |
| FY2021 | Dec 31, 2021 | -$1.59M | – |
| FY2020 | Dec 31, 2020 | -$404.69K | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$11.74M | – |
| Q1 FY2026 | Mar 31, 2026 | -$9.83M | – |
| Q4 FY2025 | Dec 31, 2025 | -$11.03M | – |
| Q3 FY2025 | Sep 30, 2025 | -$5.91M | – |
| Q2 FY2025 | Jun 30, 2025 | -$5.31M | – |
| Q1 FY2025 | Mar 31, 2025 | -$1.69M | – |
| Q4 FY2024 | Dec 31, 2024 | -$1.48M | – |
| Q3 FY2024 | Sep 30, 2024 | -$4.04M | – |
| Q2 FY2024 | Jun 30, 2024 | -$5.26M | – |
| Q1 FY2024 | Mar 31, 2024 | -$3.83M | – |
| Q4 FY2023 | Dec 31, 2023 | -$2.68M | – |
| Q3 FY2023 | Sep 30, 2023 | -$3.09M | – |
| Q2 FY2023 | Jun 30, 2023 | -$3.52M | – |
| Q1 FY2023 | Mar 31, 2023 | -$2.09M | – |
| Q4 FY2022 | Dec 31, 2022 | -$3.90M | – |
| Q3 FY2022 | Sep 30, 2022 | -$1.46M | – |
| Q2 FY2022 | Jun 30, 2022 | -$547.07K | – |
| Q1 FY2022 | Mar 31, 2022 | -$1.49M | – |
| Q4 FY2021 | Dec 31, 2021 | -$1.11M | – |
| Q3 FY2021 | Sep 30, 2021 | -$50.76K | – |
| Q2 FY2021 | Jun 30, 2021 | -$158.01K | – |
| Q1 FY2021 | Mar 31, 2021 | -$266.45K | – |
See a number that looks wrong?